Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK

EMBO Molecular Medicine

Volumn 5, Issue 11, 2013, Pages 1759-1774

  Pereira, Lorena ^a   Igea, Ana ^a   Canovas, Begoña ^a   Dolado, Ignacio ^a,c   Nebreda, Angel R ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c MOLECULAR PARTNERS AG   (Switzerland)

Author keywords

Apoptosis; Cisplatin; JNK; P38 MAPK; ROS

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PH 797804; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR CELL; TUMOR VOLUME;

APOPTOSIS; CISPLATIN; JNK; P38 MAPK; ROS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; MAP KINASE KINASE 4; MICE; MICE, TRANSGENIC; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84887033367     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201302732     Document Type: Article

References (62)

1. Bae IH, Kang SW, Yoon SH, Um HD (2006) Cellular components involved in the cell death induced by cisplatin in the absence of p53 activation. Oncol Rep 15: 1175-1180
2. Brozovic A, Osmak M (2007) Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251: 1-16
3. Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PH (2009) Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res 69: 8853-8861
4. Chiacchiera F, Simone C (2009) Inhibition of p38α unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 5: 1030-1033
5. Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK signalling. Biochem J 429: 403-417
6. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252
7. del Barco Barrantes I, Coya JM, Maina F, Arthur JS, Nebreda AR (2011) Genetic analysis of specific and redundant roles for p38α and p38β MAPKs during mouse development. Proc Natl Acad Sci USA 108: 12764-12769
8. Demuth T, Reavie LB, Rennert JL, Nakada M, Nakada S, Hoelzinger DB, Beaudry CE, Henrichs AN, Anderson EM, Berens ME (2007) MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther 6: 1212-1222
9. Dickinson RJ, Keyse SM (2006) Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119: 4607-4615
10. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR (2007) p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11: 191-205
11. Du C, Gao Z, Venkatesha VA, Kalen AL, Chaudhuri L, Spitz DR, Cullen JJ, Oberley LW, Goswami PC (2009) Mitochondrial ROS and radiation induced transformation in mouse embryonic fibroblasts. Cancer Biol Ther 8: 1962-1971
12. Elenitoba-Johnson KS, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z, Tripp S, Shami PJ, Wang LY, Coupland RW, et al (2003) Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 100: 7259-7264
13. Engel RH, Evens AM (2006) Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 11: 300-312
14. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100: 499-506
15. Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser P, Adams DJ, Wade-Martins R, Bouwman P, et al (2010) A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 16: 99-108
16. Galan-Moya EM, de la Cruz-Morcillo MA, Llanos Valero M, Callejas-Valera JL, Melgar-Rojas P, Hernadez Losa J, Salcedo M, Fernandez-Aramburo A, Ramon y Cajal S, Sanchez-Prieto R (2011) Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC. PloS ONE 6: e28406
17. Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, Verrax J (2011) Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol 82: 1384-1390
18. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ (2010) Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53: 2345-2353
19. Gutierrez-Uzquiza A, Arechederra M, Bragado P, Aguirre-Ghiso JA, Porras A (2012) p38alpha mediates cell survival in response to oxidative stress via induction of antioxidant genes: effect on the p70S6K pathway. J Biol Chem 287: 2632-2642
20. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961
21. Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, et al (2009) Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther 331: 882-895
22. Hou N, Torii S, Saito N, Hosaka M, Takeuchi T (2008) Reactive oxygen species-mediated pancreatic beta-cell death is regulated by interactions between stress-activated protein kinases, p38 and c-Jun N-terminal kinase, and mitogen-activated protein kinase phosphatases. Endocrinology 149: 1654-1665
23. Huang HL, Fang LW, Lu SP, Chou CK, Luh TY, Lai MZ (2003) DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 22: 8168-8177
24. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF (2007) p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39: 741-749
25. Joaquin M, Gubern A, Gonzalez-Nunez D, Josue Ruiz E, Ferreiro I, de Nadal E, Nebreda AR, Posas F (2012) The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress. EMBO J 31: 2952-2964
26. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661
27. Karisch R, Fernandez M, Taylor P, Virtanen C, St-Germain JR, Jin LL, Harris IS, Mori J, Mak TW, Senis YA, et al (2011) Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell 146: 826-840
28. Keyse SM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27: 253-261
29. Kurosu T, Takahashi Y, Fukuda T, Koyama T, Miki T, Miura O (2005) p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 10: 1111-1120
30. Labbe DP, Hardy S, Tremblay ML (2012) Protein tyrosine phosphatases in cancer: friends and foes! Prog Mol Biol Transl Sci 106: 253-306
31. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X, et al (2011) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 17: 1627-1635
32. Matsui Y, Ueda S, Watanabe J, Kuwabara I, Ogawa O, Nishiyama H (2007) Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res 67: 1212-1220
33. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, et al (2006) Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20: 1017-1027
34. Ostman A, Frijhoff J, Sandin A, Bohmer FD (2011) Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem 150: 345-356
35. Park IJ, Kim MJ, Park OJ, Choe W, Kang I, Kim SS, Ha J (2012) Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells. Apoptosis 17: 248-257
36. Perdiguero E, Ruiz-Bonilla V, Serrano AL, Muñoz-Cánoves P (2007) Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38α-JNK connection. Cell Cycle 6: 1298-1303
37. Phong MS, Van Horn RD, Li S, Tucker-Kellogg G, Surana U, Ye XS (2010) p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells. Mol Cell Biol 30: 3816-3826
38. Pomerance M, Quillard J, Chantoux F, Young J, Blondeau JP (2006) High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J Pathol 209: 298-306
39. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-234
40. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-189
41. Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, Royuela M (2006) The p38 transduction pathway in prostatic neoplasia. J Pathol 208: 401-407
42. Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, et al (2007) Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 104: 12117-12122
43. Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, et al (2012) Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res 72: 2350-2361
44. Ru P, Steele R, Hsueh EC, Ray RB (2011) Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer 2: 720-727
45. Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ (2003) Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63: 312-318
46. Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse SM, Perona R (2000) CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19: 5142-5152
47. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, Owen RJ, Longmore GD, Kissling GE, Arthur JS, et al (2009) p38δ Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 69: 4648-4655
48. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T (2011) Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 108: 8773-8778
49. Shen HM, Liu ZG (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 40: 928-939
50. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD (1999) Cell transformation by the superoxide-generating oxidase Mox1. Nature 401: 79-82
51. Takeda K, Noguchi T, Naguro I, Ichijo H (2008) Apoptosis signal-regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol 48: 199-225
52. Teng CH, Huang WN, Meng TC (2007) Several dual specificity phosphatases coordinate to control the magnitude and duration of JNK activation in signaling response to oxidative stress. J Biol Chem 282: 28395-28407
53. Thornton TM, Rincon M (2009) Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Inter J Biol Sci 5: 44-51
54. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591
55. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis M, Nebreda AR (2007) p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39: 750-758
56. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549
57. Wang J, Yi J (2008) Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 7: 1875-1884
58. Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J, Wang J (2010) Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol 79: 1134-1140
59. Wang SN, Lee KT, Tsai CJ, Chen YJ, Yeh YT (2012) Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest 42: 1295-1301
60. Wu WS, Wu JR, Hu CT (2008) Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev 27: 303-314
61. Xing L, Shieh HS, Selness SR, Devraj RV, Walker JK, Devadas B, Hope HR, Compton RP, Schindler JF, Hirsch JL, et al (2009) Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. Biochemistry 48: 6402-6411
62. Zimmerman R, Cerutti P (1984) Active oxygen acts as a promoter of transformation in mouse embryo C3H/10T1/2/C18 fibroblasts. Proc Natl Acad Sci USA 81: 2085-2087